MSMargaret Stalker

Margaret Stalker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Margaret Stalker has a total of 74 co-authors. Here are the top co-authors by number of shared publications:

  • Lova Sun

    Division of Hematology & Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

    3 shared publications
  • Wei-Ting Hwang

    Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

    3 shared publications
  • Alex Watts

    Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

    2 shared publications
  • Charu Aggarwal

    Division of Hematology & Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

    2 shared publications
  • Melina E. Marmarelis

    Division of Hematology & Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

    2 shared publications
  • Roger B. Cohen

    Division of Hematology & Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

    2 shared publications

Latest Publications

  • Open Access

    Incidence and Outcomes of Brain Metastasis in Pleural Mesothelioma in the Era of Immunotherapy

    by Margaret Stalker, Suzanne L. Walker, Emily Lebow, Emily Ling-Lin Pai, Alex Watts, Wei-Ting Hwang, Amir Banihashemi, Evan Anderson, Leonid Roshkovan, Sharyn I. Katz, et al.


  • Open Access

    “Off-Label” Use of Checkpoint Inhibitors in Patients With Negative or Unknown PD-L1 Status in Advanced Head and Neck Cancer

    by Margaret Stalker, Kewen Qu, Roger B. Cohen, Ronac Mamtani, Wei-Ting Hwang, Lova Sun

    Background: The KEYNOTE-048 study established the checkpoint inhibitor (CPI) pembrolizumab, with/without chemotherapy, as frontline treatment for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). However, pembrolizumab monotherapy has limited efficacy in PD-L1–negative disease. Clinical practice patterns regarding PD-L1 combined positive score (CPS) testing and PD-L1–guided treatment selection remain unknown. Patients and Methods: This retrospective analysis included patients who initiated treatment for R/M HNSCC from 2011 to 2023 in a nationwide electronic health record–derived deidentified database. Frontline therapy was categorized as CPI monotherapy, CPI with chemotherapy, or chemotherapy ± cetuximab without CPI. A subset of patients treated in 2019 and beyond (2019+ cohort) were analyzed to investigate PD-L1 testing rates, treatment patterns following FDA approval of pembrolizumab, and the proportion receiving “off-label” CPI monotherapy (single-agent use in patients with metastatic HNSCC and negative/unknown PD-L1 status). Factors associated with “off-label” use were identified using multivariable logistic regression. Results: The total cohort included 7,657 patients with a median age of 65 years (IQR, 58–72); 67% were White, 78% had a history of smoking, 66% had an ECOG performance status (PS) of 0–1, and 31% were HPV-positive. The 2019+ subset included 3,395 patients, of whom nearly half (47%) did not have a known PD-L1 CPS prior to systemic treatment initiation. The most common frontline treatment in the total cohort was CPI monotherapy (43%). CPI monotherapy use was even higher in patients aged ≥75 years (54%) and those with ECOG PS ≥2 (52%). Among the 2019+ subgroup with PD-L1 CPS negative/unknown tumors (n=1,926), 536 (28%) received CPI monotherapy “off-label.” Factors associated with “off-label” use on multivariable regression included age ≥75 years (odds ratio [OR], 1.4), community practice setting (OR, 1.5), and earlier year of treatment (OR, 1.3 per year) (all P<.05). Conclusions: Most US patients with R/M HNSCC are now receiving CPI-based therapy in the frontline setting; however, PD-L1 testing remains underutilized. “Off-label” use of CPI monotherapy in PD-L1–negative/unknown HNSCC is common, particularly among elderly patients.


  • Open Access

    Safety and Efficacy of Teclistamab in Patients With Relapsed or Refractory AL Amyloidosis

    by Margaret Stalker, Alfred Garfall, Adam Cohen, Dan T. Vogl, Mia Djulbegovic, Sandra Susanibar‐Adaniya, Edward Stadtmauer, Oxana Megherea, Adam J. Waxman

    Introduction: Teclistamab has demonstrated deep responses in patients with multiple myeloma in the MajesTEC‐1 study. However, the safety and efficacy of teclistamab in patients with AL amyloidosis are unknown.Methods: We retrospectively analyzed patients with biopsy‐proven relapsed/refractory AL amyloidosis who were treated with teclistamab from December 2022 to February 2024 at the University of Pennsylvania. The data cutoff was 2/29/24. Adverse events (AE) were extracted from the electronic medical record. Patients were assessed for hematologic and organ response per consensus guidelines.Results: Eight patients were included in this case series: median age 63 (range 59–67), 75% female, 88% White. All eight patients achieved at least very good partial response (VGPR) and had normalization of free light chains (FLC), and six (75%) patients achieved undetectable FLC levels. Of the six patients with immunofixation completed, all six (100%) achieved hematologic complete response (hCR). The median time to hematologic VGPR and hCR was 13 days (range 12–18 days) and 88 days (range 32–150 days), respectively. The median duration of follow‐up was 8.5 months (range 1–14 months). Of the five patients with cardiac involvement, four (80%) achieved a cardiac response. Of the seven patients with renal involvement, two patients already achieved renal response prior to teclistamab, and of the remaining five, three (60%) achieved renal response. Six patients (75%) developed low‐grade cytokine release syndrome (CRS). No patients developed ICANS. Neutropenia and AKI both occurred in 25% of patients, respectively.Conclusions: In this series of patients, teclistamab showed outstanding depth of response and was well‐tolerated. Teclistamab shows promise in treating patients with relapsed AL amyloidosis.


  • Open Access

    Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator’s Consortium Registry Analysis

    by Margaret Stalker, Connor B. Grady, Alex Watts, Wei-Ting Hwang, Krishna Chandrasekhara, Fangdi Sun, Geoffrey Liu, Devalben Patel, Jorge Nieva, Amanda Herrmann, et al.


  • Outcomes Following Treatment for Progression in Patients Treated With Durvalumab Consolidation in LA-NSCLC

    by Margaret Stalker, Melina Marmarelis, Corey Langer, Roger B. Cohen, Aditi Singh, Charu Aggarwal, Lova Sun


  • Open Access

    Clinical Management of Triple-Class Refractory Multiple Myeloma: A Review of Current Strategies and Emerging Therapies

    by Margaret E. Stalker, Tomer M. Mark

    Major progress has been made in the upfront treatment of multiple myeloma, but the disease ultimately relapses and leads to death in the vast majority of those afflicted. New treatment strategies and modalities are necessary to treat myeloma in relapse, particularly in cases of triple-refractory status defined by disease progression during or shortly after treatment with immunomodulatory agents, proteasome inhibitors, and anti-CD38 monoclonal antibody therapy. In this manuscript, we review recent promising developments in the treatment of triple-class refractory myeloma including bispecific antibodies and T cell engagers, chimeric antigen receptor cellular therapies, as well as chemotherapeutics with novel mechanisms of action.


  • Vascular Disorders of Pregnancy Increase Susceptibility to Neonatal Pulmonary Hypertension in High-Altitude Populations

    by Alexandra Heath-Freudenthal, Lilian Toledo-Jaldin, Inge von Alvensleben, Litzi Lazo-Vega, Rodrigo Mizutani, Margaret Stalker, Hussna Yasini, Fanny Mendizabal, Jesus Dorado Madera, William Mundo, et al.

    Background: Preeclampsia and fetal growth restriction increase cardiopulmonary disease risk for affected offspring and occur more frequently at high-altitude (≥2500 m). Retrospective studies indicate that birth to a preeclampsia woman at high altitude increases the risk of pulmonary hypertension (PH) in later life. This prospective study asked whether preeclampsia with or without fetal growth restriction exaggerated fetal hypoxia and impaired angiogenesis in the fetal lung, leading to neonatal cardiopulmonary circulation abnormalities and neonatal or infantile PH. Methods and Results: We studied 79 maternal-infant pairs (39 preeclampsia, 40 controls) in Bolivia (3600–4100 m). Cord blood erythropoietin, hemoglobin, and umbilical artery and venous blood gases were measured as indices of fetal hypoxia. Maternal and cord plasma levels of angiogenic (VEGF [vascular endothelial growth factor]) and antiangiogenic (sFlt1 [soluble fms-like tyrosine kinase]) factors were determined. Postnatal echocardiography (1 week and 6–9 months) assessed pulmonary hemodynamics and PH. Preeclampsia augmented fetal hypoxia and increased the risk of PH in the neonate but not later in infancy. Pulmonary abnormalities were confined to preeclampsia cases with fetal growth restriction. Maternal and fetal plasma sFlt1 levels were higher in preeclampsia than controls and positively associated with PH. Conclusions: The effect of preeclampsia with fetal growth restriction to increase fetal hypoxia and sFlt1 levels may impede normal development of the pulmonary circulation at high altitude, leading to adverse neonatal pulmonary vascular outcomes. Our observations highlight important temporal windows for the prevention of pulmonary vascular disease among babies born to highland residents or those with exaggerated hypoxia in utero or newborn life.